फिशर मेडिकल वेंचर्स शेयर की कीमत

Commodity Chemicals company Fischer Medical Ventures announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: For Q4FY26, revenue stood at Rs 9,773.04 lakh, registering a strong growth of 98.74% YoY compared to Rs 4,917.42 lakh in Q4FY25. However, it witnessed a slight decline of 3.33% QoQ from Rs 10,109.52 lakh in Q3FY26. For FY26, revenue was Rs 30,857.56 lakh, reflecting a massive 178.75% YoY increase against Rs 11,069.87 lakh in FY25. Total Income: Q4FY26 total income reached Rs 9,900.83 lakh, marking a 100.74% YoY surge from Rs 4,932.28 lakh in Q4FY25, but a 3.11% QoQ drop compared to Rs 10,218.32 lakh in Q3FY26. For FY26, total income stood at Rs 32,088.93 lakh, representing a growth of 186.02% YoY from Rs 11,219.07 lakh in FY25. Profit/(Loss) for the Period (Net Profit): The company reported a net loss of Rs 711.94 lakh in Q4FY26, indicating a downturn from a net profit of Rs 131.20 lakh in Q4FY25 and a net profit of Rs 1,923.47 lakh in Q3FY26. Despite the Q4 loss, the net profit For FY26 stood at Rs 3,101.95 lakh, jumping by an impressive 2,467.84% YoY from Rs 120.80 lakh in FY25. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 410.76 lakh, down by 21.31% YoY from Rs 521.97 lakh in Q4FY25, but up by 212.37% QoQ from Rs 131.50 lakh in Q3FY26. For FY26, revenue increased by 233.20% YoY to Rs 1,739.18 lakh from Rs 521.97 lakh in FY25. Total Income: For Q4FY26, total income stood at Rs 454.16 lakh, a decline of 22.62% YoY from Rs 586.90 lakh in Q4FY25, but an increase of 109.13% QoQ from Rs 217.17 lakh in Q3FY26. For FY26, total income reached Rs 2,088.52 lakh, rising by 140.70% YoY against Rs 867.67 lakh in FY25. Profit/(Loss) for the Period (Net Profit): Standalone net loss widened to Rs 898.19 lakh in Q4FY26 compared to a net loss of Rs 89.05 lakh in Q4FY25 and a net loss of Rs 166.93 lakh in Q3FY26. For FY26, the company reported a net loss of Rs 1,042.29 lakh, turning from a net profit of Rs 66.32 lakh in FY25. Business Highlights: Dividend Recommendation: The Board of Directors has recommended a final dividend of Rs 0.05/- per equity share for FY26, subject to shareholder approval at the ensuing AGM. Stock Split (Sub-division): During the year, the Board approved the sub-division of equity shares of Rs 10/- each into 10 equity shares of Re 1/- each, which became effective from the record date of September 12, 2025. Subsidiary Incorporation: During the first quarter, the company successfully completed the incorporation of FMV Global Innovation Pte Ltd. Subsidiary Restructuring: During Q4FY26, the company transferred its entire investment in Pellucidcare Health Innovations Pte Ltd (formerly FMV HealthCare PTE Ltd) to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited. Consequently, Pellucidcare Health Innovations became a step-down subsidiary. Appointment of Internal Auditors: The Board approved the appointment of M/s S. Ramanand Aiyer & Co., Chartered Accountants, as the Internal Auditors of the company for FY27. Result PDF

• ट्रेंडलाइन
• 2 सप्ताह 3 दिन पहले

कमोडिटी केमिकल्स कंपनी फिशर मेडिकल वेंचर्स ने Q3FY26 परिणामों की घोषणा की: Q3FY25 के दौरान ₹ 1,174.85 लाख के मुकाबले ₹ 10,109.52 लाख, बदलाव 760%. पीबीटी: Q3FY25 के दौरान रु. 12.44 लाख पर रु. 2,118.85 लाख. पीएटी: Q3FY25 के दौरान रु. -29.39 लाख पर रु. 1,923.48 लाख. ईपीएस: Q3FY26 के लिए 0.3. परिणाम PDF

• ट्रेंडलाइन
• 4 महीने 2 सप्ताह पहले